Logo
P

Pathos

76 employees

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.

Investor insights

Funding rounds participated in

$62M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2022

Funding rounds raised

Total raised

$62M

from 2 investors over 1 rounds

P

Pathos raised $62M on November 29, 2024

Investors: New Enterprise Associates and + 2 Other investors

FAQ